DIAMEDICA THERAPEUTICS

DIAMEDICA THERAPEUTICS

Share · CA25253X2077 · DMAC · A2N9HB (XFRA)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of DIAMEDICA THERAPEUTICS
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
6
0
0
0
No Price
29.04.2026 18:00
Current Prices from DIAMEDICA THERAPEUTICS
ExchangeTickerCurrencyLast TradePriceDaily Change
IEXG: IEX
IEX
DMAC
USD
29.04.2026 18:00
5,96 USD
-0,26 USD
-4,26 %
XNAS: NASDAQ
NASDAQ
DMAC
USD
29.04.2026 17:44
5,97 USD
-0,25 USD
-4,08 %
ESG Risk Rating
B Good
Share Float & Liquidity
Free Float 50,05 %
Shares Float 26,97 M
Shares Outstanding 53,88 M
Company Profile for DIAMEDICA THERAPEUTICS Share
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Company Data

Name DIAMEDICA THERAPEUTICS
Company DiaMedica Therapeutics Inc.
Symbol DMAC
Website https://www.diamedica.com
Primary Exchange XFRA Frankfurt
WKN A2N9HB
ISIN CA25253X2077
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dietrich John Pauls MBA
Market Capitalization 335 Mio
Country United States of America
Currency EUR
Employees 0,0 T
Address Two Carlson Parkway, 55447 Minneapolis
IPO Date 2012-08-03

Stock Splits

Date Split
15.11.2018 1:20

Ticker Symbols

Name Symbol
NASDAQ DMAC
More Shares
Investors who hold DIAMEDICA THERAPEUTICS also have the following shares in their portfolio:
BROADCOM 21/35 REGS
BROADCOM 21/35 REGS Bond
SUNCOKE EN. 21/29 REGS
SUNCOKE EN. 21/29 REGS Bond